Acute chemotherapy-induced nausea and vomiting in children with cancer: Still waiting for a common consensus on treatment A Ruggiero, D Rizzo, M Catalano, P Coccia, S Triarico, G Attiná Journal of International Medical Research 46 (6), 2149-2156, 2018 | 73 | 2018 |
The gut microbiome and efficacy of cancer immunotherapy G Roviello, LF Iannone, M Bersanelli, E Mini, M Catalano Pharmacology & Therapeutics 231, 107973, 2022 | 45 | 2022 |
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials N Sobhani, B Scaggiante, R Morris, D Chai, M Catalano, DR Tardiel-Cyril, ... Cancer treatment reviews 109, 102429, 2022 | 44 | 2022 |
Immune checkpoint inhibitors in urothelial bladder cancer: State of the art and future perspectives G Roviello, M Catalano, R Santi, VE Palmieri, G Vannini, IC Galli, ... Cancers 13 (17), 4411, 2021 | 42 | 2021 |
Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis A Inno, G Roviello, A Ghidini, A Luciani, M Catalano, S Gori, F Petrelli Critical Reviews in Oncology/Hematology 165, 103434, 2021 | 31 | 2021 |
Gut Microbiota Modulation in the Context of Immune-Related Aspects of Lactobacillus spp. and Bifidobacterium spp. in Gastrointestinal Cancers K Kaźmierczak-Siedlecka, G Roviello, M Catalano, K Polom Nutrients 13 (8), 2674, 2021 | 27 | 2021 |
Hypersensitivity to carboplatin in children with malignancy A Ruggiero, D Rizzo, M Catalano, G Attinà, R Riccardi Frontiers in Pharmacology 8, 201, 2017 | 20 | 2017 |
Current status and future perspectives in HER2 positive advanced gastric cancer G Roviello, M Catalano, LF Iannone, L Marano, M Brugia, G Rossi, ... Clinical and Translational Oncology 24 (6), 981-996, 2022 | 19 | 2022 |
Focus on biochemical and clinical predictors of response to immune checkpoint inhibitors in metastatic urothelial carcinoma: Where do we stand? G Roviello, M Catalano, S Nobili, R Santi, E Mini, G Nesi International Journal of Molecular Sciences 21 (21), 7935, 2020 | 18 | 2020 |
Interdisciplinary insights into the link between gut microbiome and gastric carcinogenesis—what is currently known? K Kaźmierczak-Siedlecka, A Daca, G Roviello, M Catalano, K Połom Gastric Cancer 25 (1), 1-10, 2022 | 17 | 2022 |
Gut microbiota modulation in the context of immune-related aspects of Lactobacillus spp. and Bifidobacterium spp. in gastrointestinal cancers K Kazmierczak-Siedlecka, G Roviello, M Catalano, K Polom Nutrients 13 (8), 2674, 2021 | 16 | 2021 |
Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand? G Roviello, G Aprile, A D’Angelo, LF Iannone, F Roviello, K Polom, E Mini, ... Gastric Cancer 24, 765-779, 2021 | 14 | 2021 |
Lung cancer immunotherapy: Beyond common immune checkpoints inhibitors M Catalano, S Shabani, J Venturini, C Ottanelli, L Voltolini, G Roviello Cancers 14 (24), 6145, 2022 | 12 | 2022 |
Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice G Roviello, M Catalano, C Ottanelli, R Giorgione, V Rossi, E Gambale, ... Medical Oncology 39 (10), 145, 2022 | 10 | 2022 |
DNA repair deficiency as circulating biomarker in prostate cancer M Catalano, D Generali, M Gatti, B Riboli, L Paganini, G Nesi, G Roviello Frontiers in Oncology 13, 1115241, 2023 | 9 | 2023 |
The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer M Catalano, G Aprile, R Conca, R Petrioli, M Ramello, G Roviello Scientific Reports 12 (1), 8244, 2022 | 9 | 2022 |
Beyond conventional: the new horizon of targeted therapy for the treatment of advanced non small cell lung cancer A Tartarone, V Lapadula, C Di Micco, G Rossi, C Ottanelli, A Marini, ... Frontiers in Oncology 11, 632256, 2021 | 9 | 2021 |
Clinical outcomes and safety of patients treated with NAb-Paclitaxel plus Gemcitabine in metastatic pancreatic cancer: The NAPA study M Catalano, G Roviello, R Conca, A D’Angelo, VE Palmieri, B Panella, ... Current Cancer Drug Targets 20 (11), 887-895, 2020 | 9 | 2020 |
Systemic sclerosis association with malignancy G Lepri, M Catalano, S Bellando-Randone, S Pillozzi, E Giommoni, ... Clinical reviews in allergy & immunology 63 (3), 398-416, 2022 | 8 | 2022 |
Combining inhibition of immune checkpoints and PARP: Rationale and perspectives in cancer treatment M Catalano, L Francesco Iannone, F Cosso, D Generali, E Mini, ... Expert Opinion on Therapeutic Targets 26 (11), 923-936, 2022 | 8 | 2022 |